Aimed Bio

0009K0· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩21,600-3.79%

2026-09-18

Financials

Valuation Metrics

Aimed Bio's Market Cap is ₩1.4T. Ranked #262 of 2,421 in KR market (top 11%), #63 of 1,640 on KOSDAQ (top 4%), #26 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	1.40T KRW	KR#262/2,421 Sec#26/231
Revenue	47.28B KRW	KR#1,826/2,421 Sec#127/231
Net Income	5.02B KRW	KR#1,208/2,421 Sec#80/231
Total Assets	198.97B KRW	KR#1,312/2,421 Sec#94/231
Net Assets	192.57B KRW	KR#974/2,421 Sec#68/231
Value
P/E	279.76x	KR#1,533/2,421 Sec#106/231
P/B	7.29x	KR#2,314/2,421 Sec#201/231
P/S	29.69x	KR#2,356/2,421 Sec#190/231
FCF Yield	1.25%	KR#1,121/2,421 Sec#80/231
Profitability
ROE	2.61%	KR#1,350/2,421 Sec#92/231
ROA	2.52%	KR#1,126/2,421 Sec#84/231
Op. Margin	43.93%	KR#17/2,421 Sec#4/231
Financial Health
Debt Ratio	3.32%	KR#18/2,421 Sec#7/231
FCF	17.51B KRW	KR#554/2,421 Sec#30/231
Cash	106.41B KRW	KR#454/2,421 Sec#21/231
Current Ratio	31.43x	KR#9/2,421 Sec#4/231
Performance
1M Return	-17.24%	KR#2,280/2,421 Sec#202/231
From 52W High	-73.07%	KR#2,261/2,421 Sec#196/231
1Y MDD	-75.31%	KR#2,186/2,421 Sec#192/231
Trading
Volume	78,157 shares	KR#910/2,421 Sec#95/231
Trading Value	1.72B KRW	KR#589/2,421 Sec#57/231
Foreign Own.	2.65%	KR#1,406/2,421 Sec#130/231
Per Share
EPS	77 KRW	KR#1,463/2,421 Sec#100/231
BPS	2,963 KRW	KR#1,868/2,421 Sec#142/231

Company Info

CEO 허남구

Founded 2018

HQ 서울특별시 송파구, KR

Website www.aimedbio.com

항체-약물 접합체(ADC) 기반 항암제를 개발하여 기술이전 하는 것을 주요 사업으로 영위함. 환자유래세포(PDC)와 환자유래 이종이식모델(PDX) 등 환자유래모델을 활용한 항체 발굴 역량과, 자체 보유한 링커-페이로드 기술을 활용한 최적의 표적과 개발 전략을 도출할 수 있는 경쟁력을 보유함. 다년간의 임상 경험을 바탕으로 미충족 의료 수요를 발굴하고 이를 신약개발 전략에 반영하는 차별성을 가지고 있음. 에임드바이오는 2018년에 설립되었으며 서울특별시 송파구에 본사를 두고 있습니다.